Noxopharm Limited

ASX:NOX.AX

0.07 (AUD) • At close July 26, 2024
Bedrijfsnaam Noxopharm Limited
Symbool NOX.AX
Munteenheid AUD
Prijs 0.072
Beurswaarde 21,041,136
Dividendpercentage 0%
52-weken bereik 0.033 - 0.165
Industrie Biotechnology
Sector Healthcare
CEO Dr. Gisela Mautner
Website https://www.noxopharm.com

An error occurred while fetching data.

Over Noxopharm Limited

Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program

Vergelijkbare Aandelen

Antisense Therapeutics Limited logo

Antisense Therapeutics Limited

ANP.AX

0.058 AUD

Microba Life Sciences Limited logo

Microba Life Sciences Limited

MAP.AX

0.2 AUD

Orthocell Limited logo

Orthocell Limited

OCC.AX

0.385 AUD

Emyria Limited logo

Emyria Limited

EMD.AX

0.044 AUD

Cynata Therapeutics Limited logo

Cynata Therapeutics Limited

CYP.AX

0.255 AUD

MedAdvisor Limited logo

MedAdvisor Limited

MDR.AX

0.535 AUD

Financiële Gegevens

Cijfers zijn in miljoenen (AUD)

Cijfers zijn in miljoenen (AUD)